Churg-Strauss Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Churg-Strauss syndrome markets are expected to exhibit a CAGR of 4.51% during 2024-2034.
The Churg-Strauss syndrome market has been comprehensively analyzed in IMARC's new report titled "Churg-Strauss Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Churg-Strauss syndrome (CSS), also called eosinophilic granulomatosis with polyangiitis, refers to a rare autoimmune disorder characterized by the inflammation of blood vessels. The condition primarily affects small and medium-sized blood vessels, leading to restricted blood flow and potential organ damage. The symptoms of the disorder can differ widely but commonly include asthma, allergic rhinitis, and elevated levels of eosinophils in the blood. As the disease progresses, individuals suffering from the illness might experience systemic indications, such as fever, weight loss, fatigue, and nerve-related problems. Organ involvement can also lead to issues in the skin, gastrointestinal tract, heart, lungs, nerves, and kidneys. Diagnosing CSS can be challenging due to its similarity to various other disorders. Medical history, physical examination, blood tests showing eosinophilia, and imaging studies are often used in the diagnostic process. Biopsies of affected tissues can also help to confirm the diagnosis by revealing characteristic blood vessel inflammation patterns.
The increasing incidences of genetic predisposition, contributing to tissue damage and blood vessel inflammation, are primarily driving the Churg-Strauss syndrome market. In addition to this, the inflating utilization of effective pharmacological interventions, such as corticosteroids, immunosuppressants, and monoclonal antibodies, to manage symptoms and curtail immune system hyperactivity is also creating a positive outlook for the market. Moreover, the widespread adoption of respiratory therapies and bronchodilators, on account of their several benefits like alleviating airway complications, enhancing lung function, and mitigating respiratory distress in patients, is further bolstering the market growth. Apart from this, the rising usage of advanced diagnostic tools, including CT scans, MRIs, ANCA testing, etc., since they help in early detection as well as timely intervention, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of plasmapheresis procedures for treating patients who don't respond to traditional drug therapies is also augmenting the market growth. This method works by removing harmful antibodies from the blood, thereby enhancing the quality of life for individuals suffering from the illness. Furthermore, the escalating application of biologic treatments that target specific pathways associated with the disease and rectify the underlying immune imbalance is expected to drive the Churg-Strauss syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Churg-Strauss syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Churg-Strauss syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Churg-Strauss syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Churg-Strauss syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Churg-Strauss syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current Churg-Strauss syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report
Market Insights
How has the Churg-Strauss syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Churg-Strauss syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Churg-Strauss syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Churg-Strauss syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of Churg-Strauss syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Churg-Strauss syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Churg-Strauss syndrome across the seven major markets?
What is the size of the Churg-Strauss syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Churg-Strauss syndrome?
What will be the growth rate of patients across the seven major markets?
Churg-Strauss Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Churg-Strauss syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Churg-Strauss syndrome market?
What are the key regulatory events related to the Churg-Strauss syndrome market?
What is the structure of clinical trial landscape by status related to the Churg-Strauss syndrome market?
What is the structure of clinical trial landscape by phase related to the Churg-Strauss syndrome market?
What is the structure of clinical trial landscape by route of administration related to the Churg-Strauss syndrome market?
The Churg-Strauss syndrome market has been comprehensively analyzed in IMARC's new report titled "Churg-Strauss Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Churg-Strauss syndrome (CSS), also called eosinophilic granulomatosis with polyangiitis, refers to a rare autoimmune disorder characterized by the inflammation of blood vessels. The condition primarily affects small and medium-sized blood vessels, leading to restricted blood flow and potential organ damage. The symptoms of the disorder can differ widely but commonly include asthma, allergic rhinitis, and elevated levels of eosinophils in the blood. As the disease progresses, individuals suffering from the illness might experience systemic indications, such as fever, weight loss, fatigue, and nerve-related problems. Organ involvement can also lead to issues in the skin, gastrointestinal tract, heart, lungs, nerves, and kidneys. Diagnosing CSS can be challenging due to its similarity to various other disorders. Medical history, physical examination, blood tests showing eosinophilia, and imaging studies are often used in the diagnostic process. Biopsies of affected tissues can also help to confirm the diagnosis by revealing characteristic blood vessel inflammation patterns.
The increasing incidences of genetic predisposition, contributing to tissue damage and blood vessel inflammation, are primarily driving the Churg-Strauss syndrome market. In addition to this, the inflating utilization of effective pharmacological interventions, such as corticosteroids, immunosuppressants, and monoclonal antibodies, to manage symptoms and curtail immune system hyperactivity is also creating a positive outlook for the market. Moreover, the widespread adoption of respiratory therapies and bronchodilators, on account of their several benefits like alleviating airway complications, enhancing lung function, and mitigating respiratory distress in patients, is further bolstering the market growth. Apart from this, the rising usage of advanced diagnostic tools, including CT scans, MRIs, ANCA testing, etc., since they help in early detection as well as timely intervention, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of plasmapheresis procedures for treating patients who don't respond to traditional drug therapies is also augmenting the market growth. This method works by removing harmful antibodies from the blood, thereby enhancing the quality of life for individuals suffering from the illness. Furthermore, the escalating application of biologic treatments that target specific pathways associated with the disease and rectify the underlying immune imbalance is expected to drive the Churg-Strauss syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Churg-Strauss syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Churg-Strauss syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Churg-Strauss syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Churg-Strauss syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Churg-Strauss syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current Churg-Strauss syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report
Market Insights
How has the Churg-Strauss syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Churg-Strauss syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Churg-Strauss syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Churg-Strauss syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of Churg-Strauss syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Churg-Strauss syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Churg-Strauss syndrome across the seven major markets?
What is the size of the Churg-Strauss syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Churg-Strauss syndrome?
What will be the growth rate of patients across the seven major markets?
Churg-Strauss Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Churg-Strauss syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Churg-Strauss syndrome market?
What are the key regulatory events related to the Churg-Strauss syndrome market?
What is the structure of clinical trial landscape by status related to the Churg-Strauss syndrome market?
What is the structure of clinical trial landscape by phase related to the Churg-Strauss syndrome market?
What is the structure of clinical trial landscape by route of administration related to the Churg-Strauss syndrome market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHURG-STRAUSS SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHURG-STRAUSS SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHURG-STRAUSS SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (???2018-2034)
7.2.4 Epidemiology by Gender (???2018-2034)
7.2.5 Diagnosed Cases (???2018-2034)
7.2.6 Patient Pool/Treated Cases (???2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (???2018-2034)
7.3.4 Epidemiology by Gender (???2018-2034)
7.3.5 Diagnosed Cases (???2018-2034)
7.3.6 Patient Pool/Treated Cases (???2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (???2018-2034)
7.4.4 Epidemiology by Gender (???2018-2034)
7.4.5 Diagnosed Cases (???2018-2034)
7.4.6 Patient Pool/Treated Cases (???2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (???2018-2034)
7.5.4 Epidemiology by Gender (???2018-2034)
7.5.5 Diagnosed Cases (???2018-2034)
7.5.6 Patient Pool/Treated Cases (???2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (???2018-2034)
7.6.4 Epidemiology by Gender (???2018-2034)
7.6.5 Diagnosed Cases (???2018-2034)
7.6.6 Patient Pool/Treated Cases (???2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (???2018-2034)
7.7.4 Epidemiology by Gender (???2018-2034)
7.7.5 Diagnosed Cases (???2018-2034)
7.7.6 Patient Pool/Treated Cases (???2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (???2018-2034)
7.8.4 Epidemiology by Gender (???2018-2034)
7.8.5 Diagnosed Cases (???2018-2034)
7.8.6 Patient Pool/Treated Cases (???2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (???2018-2034)
7.9.4 Epidemiology by Gender (???2018-2034)
7.9.5 Diagnosed Cases (???2018-2034)
7.9.6 Patient Pool/Treated Cases (???2018-2034)
8 CHURG-STRAUSS SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHURG-STRAUSS SYNDROME - UNMET NEEDS
10 CHURG-STRAUSS SYNDROME - KEY ENDPOINTS OF TREATMENT
11 CHURG-STRAUSS SYNDROME - MARKETED PRODUCTS
11.1 List of Churg-Strauss Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Nucala (Mepolizumab) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHURG-STRAUSS SYNDROME - PIPELINE DRUGS
12.1 List of Churg-Strauss Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Depemokimab - GlaxoSmithKline
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. CHURG-STRAUSS SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHURG-STRAUSS SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHURG-STRAUSS SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Churg-Strauss Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Churg-Strauss Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Churg-Strauss Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Churg-Strauss Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Churg-Strauss Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Churg-Strauss Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Churg-Strauss Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Churg-Strauss Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Churg-Strauss Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Churg-Strauss Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Churg-Strauss Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Churg-Strauss Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Churg-Strauss Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Churg-Strauss Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Churg-Strauss Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Churg-Strauss Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
16 CHURG-STRAUSS SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHURG-STRAUSS SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHURG-STRAUSS SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHURG-STRAUSS SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHURG-STRAUSS SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHURG-STRAUSS SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (???2018-2034)
7.2.4 Epidemiology by Gender (???2018-2034)
7.2.5 Diagnosed Cases (???2018-2034)
7.2.6 Patient Pool/Treated Cases (???2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (???2018-2034)
7.3.4 Epidemiology by Gender (???2018-2034)
7.3.5 Diagnosed Cases (???2018-2034)
7.3.6 Patient Pool/Treated Cases (???2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (???2018-2034)
7.4.4 Epidemiology by Gender (???2018-2034)
7.4.5 Diagnosed Cases (???2018-2034)
7.4.6 Patient Pool/Treated Cases (???2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (???2018-2034)
7.5.4 Epidemiology by Gender (???2018-2034)
7.5.5 Diagnosed Cases (???2018-2034)
7.5.6 Patient Pool/Treated Cases (???2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (???2018-2034)
7.6.4 Epidemiology by Gender (???2018-2034)
7.6.5 Diagnosed Cases (???2018-2034)
7.6.6 Patient Pool/Treated Cases (???2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (???2018-2034)
7.7.4 Epidemiology by Gender (???2018-2034)
7.7.5 Diagnosed Cases (???2018-2034)
7.7.6 Patient Pool/Treated Cases (???2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (???2018-2034)
7.8.4 Epidemiology by Gender (???2018-2034)
7.8.5 Diagnosed Cases (???2018-2034)
7.8.6 Patient Pool/Treated Cases (???2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (???2018-2034)
7.9.4 Epidemiology by Gender (???2018-2034)
7.9.5 Diagnosed Cases (???2018-2034)
7.9.6 Patient Pool/Treated Cases (???2018-2034)
8 CHURG-STRAUSS SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHURG-STRAUSS SYNDROME - UNMET NEEDS
10 CHURG-STRAUSS SYNDROME - KEY ENDPOINTS OF TREATMENT
11 CHURG-STRAUSS SYNDROME - MARKETED PRODUCTS
11.1 List of Churg-Strauss Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Nucala (Mepolizumab) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHURG-STRAUSS SYNDROME - PIPELINE DRUGS
12.1 List of Churg-Strauss Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Depemokimab - GlaxoSmithKline
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. CHURG-STRAUSS SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHURG-STRAUSS SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHURG-STRAUSS SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Churg-Strauss Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Churg-Strauss Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Churg-Strauss Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Churg-Strauss Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Churg-Strauss Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Churg-Strauss Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Churg-Strauss Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Churg-Strauss Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Churg-Strauss Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Churg-Strauss Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Churg-Strauss Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Churg-Strauss Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Churg-Strauss Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Churg-Strauss Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Churg-Strauss Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Churg-Strauss Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Churg-Strauss Syndrome - Access and Reimbursement Overview
16 CHURG-STRAUSS SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHURG-STRAUSS SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHURG-STRAUSS SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
